Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
The U.S. Food and Drug Administration (FDA) has announced the initial cohort of seven pharmaceutical companies selected to participate in…
Read More
Talawar Therapeutics and JATT II Acquisition Complete Business Combination to Advance Novel Immunology Therapeutics
In a significant development poised to reshape the landscape of immunology therapeutics, New Jersey-based Talawar Therapeutics has officially merged with…
Read More
Sobi Receives Complete Response Letter from FDA for Investigational Gout Therapy NASP, Focus on Manufacturing Deficiencies
Swedish Orphan Biovitrum (Sobi) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
The FDA’s Pursuit of "Radical Transparency" Sparks Debate on Policy Clarity
The U.S. Food and Drug Administration’s (FDA) ambitious drive towards "radical transparency," particularly through the public release of Complete Response…
Read More
Ionis Pharmaceuticals and Recordati Forge Global Partnership for Zilganersen in Alexander Disease
Ionis Pharmaceuticals has forged a significant global licensing agreement with Recordati, a prominent international pharmaceutical company, granting Recordati exclusive rights…
Read More
Absci Secures $100 Million and Advances AI-Designed Drug Candidate ABS-201 for Endometriosis and Hair Loss
Absci Corporation has successfully closed an underwritten public offering, raising approximately $100 million, a significant financial injection that will fuel…
Read More
Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…
Read More
Immunai and Boehringer Ingelheim Forge Strategic Alliance to Uncover Novel T-Cell Targets in Oncology and Autoimmune Diseases
Immunai, a leading artificial intelligence (AI) company specializing in immune system analysis, and Boehringer Ingelheim, a global biopharmaceutical giant, have…
Read MoreYOU MAY HAVE MISSED
